Pantop%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis * Zollinger-Ellison syndrome * Prevention of NSAID-induced gastric ulcers in patients at risk ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily for 4-8 weeks. For maintenance, 20-40 mg once daily. * **Zollinger-Ellison Syndrome:** 40 mg orally or intravenously twice daily, may be increased to 240 mg per day in divided doses. * **Prevention of NSAID-induced ulcers:** 20 mg orally once daily. * **Intravenous (IV):** 40 mg once daily, infused over 15 minutes. * **Nasogastric (NG) tube administration:** Pantoprazole for oral suspension can be reconstituted and administered via NG tube. ## Pediatric Dosing * **GERD/Erosive Esophagitis:** * 1 year to 5 years: 10 mg orally once daily. * 5 years to 16 years: 20 mg orally once daily. * 16 years and older: 40 mg orally once daily. * *Note: IV dosing in pediatric patients is less established and often relies on weight-based protocols. Consult local institutional guidelines.* ## Dose Adjustments * **Hepatic Impairment:** Maximum dose is 20 mg orally or intravenously once daily. * **Renal Impairment:** No dose adjustment is typically needed. ## Contraindications * Hypersensitivity to pantoprazole, other substituted benzimidazoles, or any component of the formulation. ## Adverse Effects Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness. Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, vitamin B12 deficiency. ## Key Drug Interactions * **Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole can decrease absorption of these drugs, leading to loss of virologic response. Avoid concomitant use. * **Methotrexate:** PPIs may increase methotrexate levels. Consider holding PPI during methotrexate treatment. * **CYP2C19 Substrates (e.g., clopidogrel):** Pantoprazole may decrease the efficacy of clopidogrel. Use with caution. * **Iron supplements, ketoconazole, itraconazole:** Pantoprazole decreases absorption of these drugs. ## Monitoring * Magnesium levels (especially with long-term use or concomitant diuretic use). * Bone mineral density (for patients at risk of osteoporosis with long-term therapy). * Vitamin B12 levels (with prolonged therapy). * Symptoms of *Clostridium difficile* infection. ## Clinical Pearls * Administer oral pantoprazole 30-60 minutes before a meal. * IV administration is a suitable alternative for patients unable to take oral medications. * Long-term use of PPIs is associated with increased risk of fractures, hypomagnesemia, and vitamin B12 deficiency. Use the lowest effective dose for the shortest duration necessary. * Consider stepwise reduction in dose or discontinuation when clinically appropriate. *** *Disclaimer: This information is intended for healthcare professionals and does not substitute for professional medical advice. Always consult the most current prescribing information and institutional protocols for definitive patient management.*